Luteolin decreases atherosclerosis in LDL receptor‑deficient mice via a mechanism including decreasing AMPK‑SIRT1 signaling in macrophages

Li,Jiang; Dong,Jian‑Zeng; Ren,Yan‑Long; Zhu,Jia‑Jia; Cao,Jia‑Ning; Zhang,Jing; Pan,Li‑Li

doi:10.3892/etm.2018.6499

Luteolin decreases atherosclerosis in LDL receptor‑deficient mice via a mechanism including decreasing AMPK‑SIRT1 signaling in macrophages

Authors:
- Jiang Li
- Jian‑Zeng Dong
- Yan‑Long Ren
- Jia‑Jia Zhu
- Jia‑Ning Cao
- Jing Zhang
- Li‑Li Pan
View Affiliations

Affiliations: Department of Cardiology, Beijing An Zhen Hospital, Capital Medical University, Beijing 100029, P.R. China, Department of Rheumatology, Beijing An Zhen Hospital, Capital Medical University, Beijing 100029, P.R. China
Published online on: July 20, 2018 https://doi.org/10.3892/etm.2018.6499
Pages: 2593-2599

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lipid metabolism dysfunction and inflammatory infiltration into arterial walls are associated with the initiation and progression of atherosclerosis. Luteolin has been reported to possess anti‑inflammatory actions and protect against tumor necrosis factor‑α (TNF‑α)‑induced vascular inflammation, monocyte adhesion to endothelial cells and the formation of lipid‑laden macrophages in vitro. However, the role of luteolin in atherosclerosis and the associated vascular inflammatory remains to be elucidated. The aim of the present study was to investigate the effects of luteolin on plaque development, lipid accumulation and macrophage inflammation low‑density lipoprotein receptor‑deficient (LDLR‑/‑) mice with atherosclerosis, as well as the underlying mechanisms in ox‑induced THP‑1‑derived macrophages. Firstly, 9‑week‑old male C57BL/6 mice were fed a standard chow diet, western diet or western diet supplemented with 100 mg/kg luteolin for 14 weeks. The results of histological staining revealed that 100 mg/kg dietary luteolin ameliorated western diet‑induced atherosclerotic plaque development and lipid accumulation in the abdominal aorta. Furthermore, total cholesterol, triglyceride and LDL‑cholesterol levels were decreased in the plasma of western diet + luteolin mice compared with those fed with a western diet alone. Quantitative polymerase chain reaction analysis revealed that dietary luteolin inhibited the expression of cluster of differentiation 68, macrophage chemoattractant protein 2 and inflammatory cytokines, including interleukin‑6 (IL‑6) and TNF‑α. Mechanistically, luteolin decreased the total cholesterol level as well as macrophage chemokine and inflammatory cytokine expression in THP‑1‑derived macrophages via AMP‑activated protein kinase (AMPK)‑Sirtuin (SIRT)1 signaling following induction with oxidized low‑density lipoprotein. The results of the present study suggest that luteolin prevents plaque development and lipid accumulation in the abdominal aorta by decreasing macrophage inflammation during atherosclerosis, which is mediated by mechanisms including AMPK‑SIRT1 signaling.

View Figures

View References

1	Glass CK and Witztum JL: Atherosclerosis. The road ahead. Cell. 104:503–516. 2001. View Article : Google Scholar : PubMed/NCBI
2	Celermajer DS, Chow CK, Marijon E, Anstey NM and Woo KS: Cardiovascular disease in the developing world: Prevalences, patterns, and the potential of early disease detection. J Am Coll Cardiol. 60:1207–1216. 2012. View Article : Google Scholar : PubMed/NCBI
3	Ross R: Atherosclerosis-an inflammatory disease. N Engl J Med. 340:115–126. 1999. View Article : Google Scholar : PubMed/NCBI
4	Andersson J, Libby P and Hansson GK: Adaptive immunity and atherosclerosis. Clin Immunol. 134:33–46. 2010. View Article : Google Scholar : PubMed/NCBI
5	Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 352:1685–1695. 2005. View Article : Google Scholar : PubMed/NCBI
6	Weber C, Zernecke A and Libby P: The multifaceted contributions of leukocyte subsets to atherosclerosis: Lessons from mouse models. Nat Rev Immunol. 8:802–815. 2008. View Article : Google Scholar : PubMed/NCBI
7	Seimon T and Tabas I: Mechanisms and consequences of macrophage apoptosis in atherosclerosis. J Lipid Res. 50 Suppl:S382–S387. 2009. View Article : Google Scholar : PubMed/NCBI
8	Renier G, Skamene E, DeSanctis JB and Radzioch D: High macrophage lipoprotein lipase expression and secretion are associated in inbred murine strains with susceptibility to atherosclerosis. Arterioscler Thromb. 13:190–196. 1993. View Article : Google Scholar : PubMed/NCBI
9	Babaev VR, Fazio S, Gleaves LA, Carter KJ, Semenkovich CF and Linton MF: Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in vivo. J Clin Invest. 103:1697–1705. 1999. View Article : Google Scholar : PubMed/NCBI
10	Arts IC and Hollman PC: Polyphenols and disease risk in epidemiologic studies. Am J Clin Nutr. 81 1 Suppl:S317–S325. 2005. View Article : Google Scholar
11	Maron DJ: Flavonoids for reduction of atherosclerotic risk. Curr Atheroscler Rep. 6:73–78. 2004. View Article : Google Scholar : PubMed/NCBI
12	Mennen LI, Sapinho D, de Bree A, Arnault N, Bertrais S, Galan P and Hercberg S: Consumption of foods rich in flavonoids is related to a decreased cardiovascular risk in apparently healthy French women. J Nutr. 134:923–926. 2004. View Article : Google Scholar : PubMed/NCBI
13	Cao J, Zhang Y, Chen W and Zhao X: The relationship between fasting plasma concentrations of selected flavonoids and their ordinary dietary intake. Br J Nutr. 103:249–255. 2010. View Article : Google Scholar : PubMed/NCBI
14	López-Lázaro M: Distribution and biological activities of the flavonoid luteolin. Mini Rev Med Chem. 9:31–59. 2009. View Article : Google Scholar : PubMed/NCBI
15	Nazari QA, Kume T, Takada-Takatori Y, Izumi Y and Akaike A: Protective effect of luteolin on an oxidative-stress model induced by microinjection of sodium nitroprusside in mice. J Pharmacol Sci. 122:109–117. 2013. View Article : Google Scholar : PubMed/NCBI
16	Si H, Wyeth RP and Liu D: The flavonoid luteolin induces nitric oxide production and arterial relaxation. Eur J Nutr. 53:269–275. 2014. View Article : Google Scholar : PubMed/NCBI
17	Jang S, Dilger RN and Johnson RW: Luteolin inhibits microglia and alters hippocampal-dependent spatial working memory in aged mice. J Nutr. 140:1892–1898. 2010. View Article : Google Scholar : PubMed/NCBI
18	Jia Z, Nallasamy P, Liu D, Shah H, Li JZ, Chitrakar R, Si H, McCormick J, Zhu H, Zhen W and Li Y: Luteolin protects against vascular inflammation in mice and TNF-alpha-induced monocyte adhesion to endothelial cells via suppressing IΚBα/NF-κB signaling pathway. J Nutr Biochem. 26:293–302. 2015. View Article : Google Scholar : PubMed/NCBI
19	Xia F, Wang C, Jin Y, Liu Q, Meng Q, Liu K and Sun H: Luteolin protects HUVECs from TNF-α-induced oxidative stress and inflammation via its effects on the Nox4/ROS-NF-κB and MAPK pathways. J Atheroscler Thromb. 21:768–783. 2014. View Article : Google Scholar : PubMed/NCBI
20	Zhang BC, Zhang CW, Wang C, Pan DF, Xu TD and Li DY: Luteolin attenuates foam cell formation and apoptosis in Ox-LDL-stimulated macrophages by enhancing autophagy. Cell Physiol Biochem. 39:2065–2076. 2016. View Article : Google Scholar : PubMed/NCBI
21	Makino J, Nakanishi R, Kamiya T, Hara H, Ninomiya M, Koketsu M and Adachi T: Luteolin suppresses the differentiation of THP-1 cells through the Inhibition of NOX2 mRNA expression and the membrane translocation of p47phox. J Nat Prod. 76:1285–1290. 2013. View Article : Google Scholar : PubMed/NCBI
22	Kim MS, Kim DS, Kim HS, Kang SW and Kang YH: Inhibitory effects of luteolin on transendothelial migration of monocytes and formation of lipid-laden macrophages. Nutrition. 28:1044–1054. 2012. View Article : Google Scholar : PubMed/NCBI
23	Dong J, Zhang X, Zhang L, Bian HX, Xu N, Bao B and Liu J: Quercetin reduces obesity-associated ATM infiltration and inflammation in mice: A mechanism including AMPKα1/SIRT1. J Lipid Res. 55:363–374. 2014. View Article : Google Scholar : PubMed/NCBI
24	Fullerton MD, Steinberg GR and Schertzer JD: Immunometabolism of AMPK in insulin resistance and atherosclerosis. Mol Cell Endocrinol. 366:224–234. 2013. View Article : Google Scholar : PubMed/NCBI
25	Vasamsetti SB, Karnewar S, Kanugula AK, Thatipalli AR, Kumar JM and Kotamraju S: Metformin inhibits monocyte-to-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: Potential role in atherosclerosis. Diabetes. 64:2028–2041. 2015. View Article : Google Scholar : PubMed/NCBI
26	Motoshima H, Goldstein BJ, Igata M and Araki E: AMPK and cell proliferation-AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol. 574:63–71. 2006. View Article : Google Scholar : PubMed/NCBI
27	Zelicoff AP: Multifactorial risk assessment for atherosclerotic cardiovascular disease. JAMA. 313:971–972. 2015. View Article : Google Scholar : PubMed/NCBI
28	Mahé I and Bergmann JF: Multifactorial cardiovascular risk. Presse Med. 29:47–54. 2000.(In French). PubMed/NCBI
29	Libby P, Ridker PM and Hansson GK: Progress and challenges in translating the biology of atherosclerosis. Nature. 473:317–325. 2011. View Article : Google Scholar : PubMed/NCBI
30	Zhang L, Han YJ, Zhang X, Wang X, Bao B, Qu W and Liu J: Luteolin reduces obesity-associated insulin resistance in mice by activating AMPKα1 signalling in adipose tissue macrophages. Diabetologia. 59:2219–2228. 2016. View Article : Google Scholar : PubMed/NCBI
31	Chen CY, Peng WH, Tsai KD and Hsu SL: Luteolin suppresses inflammation-associated gene expression by blocking NF-kappaB and AP-1 activation pathway in mouse alveolar macrophages. Life Sci. 81:1602–1614. 2007. View Article : Google Scholar : PubMed/NCBI
32	Chen D, Bi A, Dong X, Jiang Y, Rui B, Liu J, Yin Z and Luo L: Luteolin exhibits anti-inflammatory effects by blocking the activity of heat shock protein 90 in macrophages. Biochem Biophys Res Commun. 443:326–332. 2014. View Article : Google Scholar : PubMed/NCBI
33	Moore KJ, Sheedy FJ and Fisher EA: Macrophages in atherosclerosis: A dynamic balance. Nat Rev Immunol. 13:709–721. 2013. View Article : Google Scholar : PubMed/NCBI
34	Galkina E and Ley K: Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol. 27:2292–2301. 2007. View Article : Google Scholar : PubMed/NCBI
35	Winnik S, Stein S and Matter CM: SIRT1 - an anti-inflammatory pathway at the crossroads between metabolic disease and atherosclerosis. Curr Vasc Pharmacol. 10:693–696. 2012. View Article : Google Scholar : PubMed/NCBI
36	Zhang MJ, Zhou Y, Chen L, Wang X, Long CY, Pi Y, Gao CY, Li JC and Zhang LL: SIRT1 improves VSMC functions in atherosclerosis. Prog Biophys Mol Biol. 121:11–15. 2016. View Article : Google Scholar : PubMed/NCBI
37	Yang Z, Kahn BB, Shi H and Xue BZ: Macrophage alpha1 AMP-activated protein kinase (alpha1AMPK) antagonizes fatty acid-induced inflammation through SIRT1. J Biol Chem. 285:19051–19059. 2010. View Article : Google Scholar : PubMed/NCBI